Bionomics IPO Presentation Deck

BNC210 Potentially Addresses the Shortcomings of Existing PTSD Therapies Proof of Biology In healthy subjects (anti-panic) and GAD patients (anti-anxiety) Novel Mechanism of Action Bionomics BNC210 Potential to treat PTSD and Other Trauma and Stress-Related Disorders Demonstrated Target Engagement At nicotinic receptor in healthy subjects Large Market Potential For treatment of multiple psychiatric indications Strong Safety Database In humans - 12 clinical trials, exposure in -400 subjects DRUG CURRENT TREATMENTS FOR PTSD NO FAST WITHDRAWAL NO MEMORY ACTING SEDATION SYNDROME IMPAIRMENT IMPAIRMENT NO NO MOTOR X ✔ SSRIs/SNRIS X BNC210 IS DESIGNED TO PROVIDE POTENTIAL ADVANTAGES COMPARED TO CURRENT THERAPIES* "Potential benefits bosed on analysis of data from separate studies ond not on results that night have been obtained from head to head studies Such dots may not be directly comparable due to differences e shady protocols conditions and patient populations Accordingly cross-to comparisons may not be able predictors of the relative efficacy or other benefits of BMC210 compared to existing therapies or other product candidates that may be approved or care in development for the treatment of PTSD or SAD 1 ces Pac and certain other See Serotonin Reuptake inhibit/SAR (Serotonin-Norening Rekenin 19

View entire presentation